Wegovy Compounding Legal Status: What Patients and Prescribers Need to Know in 2025

When Was Wegovy FDA Approved, and What Did That Approval Cover?

The FDA approved Wegovy on June 4, 2021, under New Drug Application (NDA) 215256, making it the first GLP-1 receptor agonist approved specifically for chronic weight management since lorcaserin was withdrawn in 2020. The approval covered semaglutide 2.4 mg administered as a once-weekly subcutaneous injection in adults with an initial body mass index of 30 kg/m² or higher, or 27 kg/m² or higher in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. In 2023, the FDA extended the indication to include adolescents aged 12 and older with obesity.

The Key Evidence Behind the Approval

The approval rested primarily on the STEP clinical program. In STEP-1 (N=1,961), once-weekly semaglutide 2.4 mg produced a mean body weight reduction of 14.9% at 68 weeks compared with 2.4% for placebo (P<0.001) [1]. Participants also showed clinically meaningful reductions in waist circumference, blood pressure, and fasting glucose. The trial enrolled adults without type 2 diabetes, and adherence to a reduced-calorie diet and increased physical activity was required in both arms, a design detail the label preserves as part of the approved indication.

How the Approval Differs from Ozempic

Semaglutide 1.0 mg (Ozempic, NDA 209637) had already been approved for type 2 diabetes in 2017. Wegovy's NDA is entirely separate, covers a different dose, a different indication, and a different pen device. The distinction matters because a compounded product cannot legally be considered bioequivalent to both NDAs simultaneously. Prescribers who used Ozempic off-label for weight loss before Wegovy's approval were operating outside labeled use, and that pathway became largely moot once Wegovy launched commercially.

What Does the Wegovy Label Actually Say?

The Wegovy prescribing information, available through Drugs@FDA under NDA 215256, specifies dose escalation, contraindications, warnings, and post-marketing commitments [2]. Understanding the label is essential for both compounding legal analysis and clinical prescribing.

Dose Escalation Schedule

The label mandates a fixed titration to minimize gastrointestinal side effects. Patients begin at 0.25 mg once weekly for four weeks, then advance through 0.5 mg, 1.0 mg, and 1.7 mg, reaching the maintenance dose of 2.4 mg at week 17. If patients cannot tolerate the 2.4 mg dose, a temporary dose reduction to 1.7 mg is permitted for four weeks before re-attempting 2.4 mg. This titration schedule is part of the approved labeling and is not replicated on any compounded product's certificate of analysis.

Black-Box Warning and Key Contraindications

The label carries a boxed warning regarding thyroid C-cell tumors. In rodent studies, semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. The FDA states: "It is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans" [2]. Wegovy is therefore contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Additional contraindications include prior serious hypersensitivity reaction to semaglutide or any excipient in the formulation. The label also flags acute pancreatitis as a serious warning, noting that patients should discontinue Wegovy promptly if pancreatitis is suspected.

Post-Marketing Commitments Required by FDA

As a condition of approval, Novo Nordisk agreed to conduct post-marketing studies including a 5-year cardiovascular outcomes trial (SELECT, NCT03574597), a dedicated pediatric study in adolescents 12 through 17 years, and ongoing pharmacovigilance through FDA Sentinel. SELECT enrolled 17,604 adults with pre-existing cardiovascular disease but without diabetes and reported a 20% relative risk reduction in major adverse cardiovascular events at a median of 33.5 months of follow-up, data that the FDA used to update Wegovy's label in March 2024 to include a cardiovascular risk reduction indication [3].

What Is the Legal Status of Compounded Semaglutide in 2025?

This is where patients and prescribers need precise, current information. The legal permissibility of compounded semaglutide changed dramatically between 2022 and mid-2025, driven entirely by FDA shortage designations.

How the Shortage Created a Legal Window

Under Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies and outsourcing facilities may legally produce copies of FDA-approved drugs when those drugs appear on the FDA's drug shortage list [4]. Wegovy experienced genuine, documented supply shortages beginning in 2022 as commercial demand rapidly outpaced Novo Nordisk's manufacturing capacity. The FDA added semaglutide injection to the drug shortage list, which opened a legal window for compounders to produce semaglutide-containing preparations without violating the prohibition on copying approved drugs.

During this period, hundreds of 503A pharmacies and dozens of 503B outsourcing facilities began producing compounded semaglutide. These products varied widely in concentration, excipients, and added ingredients. Some compounders added vitamin B12, cyanocobalamin, or other substances not present in Wegovy, creating combination products whose safety and bioavailability have not been studied in controlled trials.

The FDA's Shortage Resolution and Its Consequences

On May 22, 2025, the FDA officially declared the semaglutide injection shortage resolved [5]. That declaration had immediate legal consequences under 21 U.S.C. § 503B(a)(5): outsourcing facilities had until May 22, 2025, to cease producing new batches of compounded semaglutide. For 503A pharmacies, the FDA provided an additional 60-day transition window, allowing pharmacies to dispense existing compounded product to patients who were already established on therapy, but only until that window closes.

After the transition periods expire, producing or dispensing compounded semaglutide without a patient-specific, non-commercially-available clinical justification becomes legally impermissible under federal law. A patient's inability to afford brand Wegovy does not constitute a legal basis for compounding under 503A.

What About "Personalized" or "Bioidentical" Compounded Semaglutide?

Some compounders have argued that adding ingredients, changing concentration, or altering the formulation makes their product a "different" drug that falls outside the copying prohibition. The FDA has explicitly rejected this argument in formal guidance. The agency's March 2024 guidance on compounding drug products that are essentially copies of commercially available drugs states that adding a "minor difference" in ingredients does not change the legal analysis if the compounder cannot demonstrate a clinical difference for an identified patient [6]. In practice, a compounder adding B12 to semaglutide cannot escape the copy prohibition simply by virtue of that addition.

State Pharmacy Board Enforcement

Federal law sets the floor, but state pharmacy boards add an additional enforcement layer. Several states, including California, Texas, and Florida, have issued formal guidance or cease-and-desist actions against specific pharmacies compounding semaglutide after the shortage resolution. Prescribers practicing in these states face dual liability exposure at both the federal and state level if they continue writing prescriptions directed toward compounding pharmacies for semaglutide after the legal windows close.

The HealthRX clinical team developed the following decision framework for prescribers evaluating patient requests for compounded semaglutide after May 2025. Three questions determine legality: (1) Is the patient's clinical need documented as requiring a formulation not available commercially? (2) Has the prescriber confirmed the compounding pharmacy's current 503A or 503B registration status? (3) Has the prescriber documented in the chart that no commercially available alternative is clinically appropriate? If any answer is no, prescribing toward a compounding pharmacy for semaglutide carries material legal risk.

Wegovy Safety: What Post-Market Data Shows Beyond the Label

The label captures pre-approval trial data, but three years of real-world use have added texture to the safety picture. FDA Sentinel and published pharmacovigilance studies have identified several signals worth discussing with patients.

Gastrointestinal Events

Nausea, vomiting, diarrhea, and constipation remain the most common adverse events, consistent with the STEP trials. STEP-1 reported nausea in 44% of the semaglutide arm versus 16% in the placebo arm [1]. Most gastrointestinal symptoms are transient and peak during dose escalation. Dose reduction to 1.7 mg for four weeks, as permitted by the label, reduces discontinuation rates in clinical practice.

Gastroparesis and Aspiration Risk

A 2023 pharmacoepidemiology study published in JAMA (N=5,401,535 person-years of follow-up) found that GLP-1 receptor agonists as a class were associated with a higher incidence of gastroparesis compared with bupropion-naltrexone (adjusted hazard ratio 3.67, 95% CI 1.15 to 11.90) [7]. The FDA added a specific warning about the risk of pulmonary aspiration during procedures requiring anesthesia or deep sedation to GLP-1 class labeling in 2023. Anesthesiologists at major medical centers now routinely ask patients about GLP-1 use before elective procedures.

Cardiovascular Effects: The SELECT Trial Signal

The SELECT trial results updated the safety picture favorably for patients with pre-existing atherosclerotic cardiovascular disease. Among 17,604 participants, the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group, a 20% relative risk reduction (hazard ratio 0.80, 95% CI 0.72 to 0.90, P<0.001) [3]. That signal was strong enough for the FDA to add a cardiovascular risk reduction statement to Wegovy's indication, the first GLP-1 approval for this purpose in people without diabetes.

Heart Rate Increase

A consistent finding across GLP-1 trials is a modest increase in resting heart rate. STEP-1 showed a mean increase of approximately 1 to 4 beats per minute with semaglutide versus placebo. The clinical significance for most patients is low, but prescribers should exercise caution in patients with a history of tachyarrhythmia or those taking other agents that increase heart rate.

Suicidal Ideation: An Ongoing FDA Review

The FDA initiated a review of suicidal ideation and behavior signals across GLP-1 receptor agonists in 2023 following reports in the FDA Adverse Event Reporting System (FAERS). As of early 2025, the FDA concluded that available data do not support a causal association between semaglutide and suicidal ideation [8]. The label does not currently carry a warning for this signal, though monitoring continues. Prescribers should apply standard psychiatric screening at baseline and follow-up visits.

How the Compounding Shutdown Affects Access and Cost

The legal closure of the compounding window has real consequences for patients who relied on compounded semaglutide as a lower-cost alternative to brand Wegovy.

The Cost Gap Is Significant

Brand Wegovy carries a list price of approximately $1,349 per month in the United States without insurance coverage. Compounded semaglutide was available from 503A pharmacies at prices ranging from $150 to $400 per month during the shortage period. For patients without employer-sponsored coverage or Medicare Part D GLP-1 coverage, the cost differential is not trivial.

Novo Nordisk's Patient Assistance Programs

Novo Nordisk operates the NovoCare savings program, which caps out-of-pocket costs at $0 per month for eligible commercially insured patients and provides a Patient Assistance Program (PAP) for uninsured patients with household income at or below 400% of the federal poverty level. Prescribers should direct cost-concerned patients to NovoCare before concluding that compounded semaglutide is the only accessible option.

Insurance Coverage Trends

As of 2025, Medicare Part D plans cover Wegovy for the cardiovascular risk reduction indication in patients who meet SELECT trial criteria (BMI ≥27 with established cardiovascular disease). The Inflation Reduction Act did not specifically mandate obesity drug coverage, but the cardiovascular indication opened a billing pathway under ICD-10 codes for atherosclerotic cardiovascular disease. Commercial insurer coverage remains variable, and prior authorization criteria differ substantially by plan.

What Prescribers Must Document When Prescribing Wegovy

Proper documentation protects prescribers and supports prior authorization approvals. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states that prescribers should document "baseline BMI, weight-related comorbidities, prior weight-loss treatment attempts, and the rationale for pharmacotherapy selection" before initiating any anti-obesity medication [9].

Required Elements for Wegovy Prescriptions

• Confirmed BMI at or above the approved threshold
• Documentation of at least one comorbidity if BMI is between 27 and 29.9 kg/m²
• Absence of contraindicated conditions (personal or family history of MTC or MEN 2)
• Baseline thyroid palpation or imaging if clinical suspicion warrants
• Patient counseling on the boxed warning, which must be documented in the chart

Monitoring Intervals

The label does not specify a formal monitoring schedule beyond the titration timeline, but the American Association of Clinical Endocrinology (AACE) 2022 obesity algorithm recommends reassessment at 16 weeks to evaluate efficacy [10]. Patients who have not achieved at least 5% body weight reduction by 16 weeks at the highest tolerated dose are unlikely to be long-term responders, and the AACE guidance suggests considering discontinuation or switching agents at that threshold.

The International Regulatory Picture

Wegovy's legal status outside the United States follows a parallel but not identical path.

European Medicines Agency Approval

The EMA granted marketing authorization for Wegovy (semaglutide 2.4 mg) in January 2022 under the brand name Wegovy in the EU. The European Public Assessment Report (EPAR) is publicly available and mirrors the STEP program data that supported the FDA's approval. Compounding of semaglutide in EU member states is governed by national pharmacy laws, and unlike the U.S. 503A/503B framework, most EU states do not have a shortage-triggered compounding exception as permissive as the American model.

United Kingdom

The Medicines and Healthcare products Regulatory Agency (MHRA) approved Wegovy in September 2023. The UK Medicines and Healthcare products Regulatory Agency issued a specific warning in 2024 about unlicensed compounded semaglutide products circulating through online pharmacies, noting that at least one product tested by the agency contained no detectable semaglutide. Patients ordering compounded semaglutide from offshore pharmacies face unknown product quality and no regulatory recourse.